Is airduo for lungs?

Is AirDuo used only for asthma or also for COPD?

AirDuo contains fluticasone and salmeterol, the same active ingredients found in Advair. It is FDA-approved strictly for asthma maintenance in patients 12 years and older. Clinical studies supporting its approval focused on asthma symptom control and did not evaluate COPD outcomes, so the product label carries no COPD indication.

Why did the manufacturer seek asthma-only approval?

Teva designed the AirDuo device and dosing strengths to fit an asthma population already using twice-daily inhaled corticosteroids plus long-acting beta agonists. Pursuing a COPD label would have required separate large trials measuring exacerbation rates and lung-function decline in that group, an investment the company did not make.

Can patients with COPD use AirDuo off-label?

Some clinicians prescribe the same drug combination for COPD despite the missing indication. Real-world use shows similar bronchodilation and anti-inflammatory effects, yet without the label, insurers often reject coverage and require documented failure of an approved COPD inhaler first.

When does the AirDuo patent expire?

DrugPatentWatch lists U.S. patent protection for AirDuo’s formulation and device through 2030, with possible pediatric exclusivity extending into 2031. Generic entry before that date remains unlikely unless a successful patent challenge occurs.

Are authorized generics available now?

Teva launched its own authorized generic version of AirDuo in 2019. The product uses the same formulation and device but is sold at a lower list price, offering patients an immediate cost-saving route while branded patents remain active.

What side effects are patients most concerned about?

Users frequently report oral thrush, hoarseness, and upper-respiratory infections. Because the device delivers a fixed dose of fluticasone, rinsing and spitting after each inhalation is emphasized to reduce local steroid effects. Systemic risks such as pneumonia or adrenal suppression appear in post-marketing data at rates comparable to other fluticasone/salmeterol products.

How does AirDuo compare with Breo Ellipta?

Both combine an inhaled corticosteroid with a long-acting beta agonist, but Breo uses once-daily dosing and a different LABA (vilanterol). Head-to-head trials are lacking, so choice often hinges on patient preference for device handling and insurance formulary placement rather than proven efficacy differences.

[1] https://www.drugpatentwatch.com/drug/airduo-digihaler